State Street Corp Aerie Pharmaceuticals Inc Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$6.37 - $15.23 $48,889 - $116,890	7,675 Added 0.81%	951,675 $14.4 Million
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $751,895 - $1.39 Million	-151,898 Reduced 13.86%	944,000 $7.08 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $78,311 - $136,073	13,885 Added 1.28%	1,095,898 $9.97 Million
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $856,812 - $1.63 Million	122,053 Added 12.71%	1,082,013 $7.6 Million
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $362,772 - $532,941	-32,047 Reduced 3.23%	959,960 $10.9 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $2.37 Million - $2.97 Million	156,548 Added 18.74%	992,007 $15.9 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $1.84 Million - $2.94 Million	-140,434 Reduced 14.39%	835,459 $14.9 Million
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $242,819 - $385,796	-26,625 Reduced 2.66%	975,893 $13.2 Million
Q3 2020 Nov 10, 2020	SELL	$10.46 - $14.46 $1.29 Million - $1.79 Million	-123,738 Reduced 10.99%	1,002,518 $11.8 Million
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $638,100 - $857,712	-53,175 Reduced 4.51%	1,126,256 $16.6 Million
Q1 2020 May 11, 2020	BUY	$11.84 - $25.52 $14 Million - $30.1 Million	1,179,431 New	1,179,431 $15.9 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.